Fibogel3.5 gm/5.4 gm

Fibogel is a bulk-forming fibre laxative derived from the husk of Plantago ovata seeds. It is indicated for:

Established uses

• Constipation: Relief of occasional or chronic constipation, and to maintain regular bowel movement in patients who need to avoid straining (e.g. after rectal/anal surgery, in hemorrhoids, or during pregnancy).
• Irritable bowel syndrome (IBS): Adjunct symptomatic management of IBS, particularly constipation-predominant IBS, where increased dietary fibre intake is recommended by clinical guidelines.

Adjunct/supportive uses

• Dietary fibre supplementation: Used as an adjunct, together with diet and lifestyle modification, to help lower elevated LDL-cholesterol as part of management of mild-to-moderate hyperlipidemia.
• Glycemic control support: Used as an adjunct to diet in type 2 diabetes mellitus to help moderate post-prandial blood glucose rise; it is not a substitute for prescribed antidiabetic therapy.

Fibogel is not intended for rapid relief of constipation; onset of action typically takes 12-72 hours.

Each dose of Ispaghula Husk typically supplies purified, dried husk (epidermis and seed coat) obtained from the seeds of Plantago ovata Forssk., standardized for soluble mucilage/fibre content. It is available as granules, powder for oral suspension, or capsules, usually formulated without added sugar in diabetic-friendly presentations. No systemically-absorbed active chemical entity is present; the therapeutic effect comes from the hydrophilic mucilloid fibre itself.

Fibogel (psyllium husk) is a natural, hydrophilic, bulk-forming laxative obtained from the seed husk of the plant Plantago ovata. When mixed with water and swallowed, it absorbs fluid in the intestine and swells to form a soft, bulky, gelatinous mass that promotes normal peristalsis and softens stool consistency.

Because it is minimally fermented and not systemically absorbed, Fibogel is widely used as a first-line, non-stimulant option for chronic constipation and as a dietary fibre supplement.

Fibogel belongs to the class of bulk-forming laxatives (dietary fibre / hydrophilic mucilloid laxatives).

Ispaghula Husk consists of the mucilaginous polysaccharide fraction of the Plantago ovata seed coat. On contact with water in the gastrointestinal tract, it absorbs several times its weight in fluid and forms a viscous gel, increasing faecal bulk and moisture content.

Mechanism

• Increased stool bulk and water content mechanically stimulate peristalsis, reducing colonic transit time.
• The soluble fibre fraction is partially fermented by colonic bacteria, producing short-chain fatty acids and increasing bacterial mass, which contributes further to stool bulk.
• In the gut lumen, the gel-forming fibre can bind bile acids and slow glucose absorption, which underlies its adjunct cholesterol-lowering and glycemic effects.

Ispaghula Husk is not systemically absorbed, so it has no pharmacokinetic (absorption/distribution/metabolism/excretion) profile in the conventional sense; its action is entirely local, within the gastrointestinal lumen.

Fibogel should be mixed with a full glass (at least 150 mL) of cold water, fruit juice, or milk, stirred well, and taken orally immediately, followed by another glass of liquid. It should not be swallowed dry. To avoid reduced absorption of other oral medicines, other drugs should be taken at least 1-2 hours before or after Fibogel.

Fibogel can physically bind or delay gastrointestinal absorption of certain oral medicines if taken together, reducing their effectiveness. Clinically significant interactions include:

• Digoxin: Reduced absorption and lower serum digoxin levels when taken with Fibogel; separate dosing by at least 2 hours.
• Lithium: Reduced absorption, potentially lowering serum lithium levels; separate dosing and monitor lithium levels if used together.
• Carbamazepine and certain other anticonvulsants: Reduced bioavailability with concurrent intake; separate dosing.
• Warfarin and other oral anticoagulants: Altered anticoagulant absorption/effect reported; separate dosing and monitor INR if co-administered.
• Oral medicines generally: As a rule, any oral medication should be taken at least 1-2 hours before or after Fibogel to avoid reduced absorption.

Fibogel is generally well tolerated. Reported adverse effects include:

• Common: Abdominal bloating, flatulence, and mild abdominal cramping, especially when starting therapy or with inadequate fluid intake; usually improves with continued use and gradual dose titration.
• Uncommon: Nausea, mild diarrhoea, or a sensation of intestinal fullness.
• Rare but serious: Hypersensitivity reactions (skin rash, urticaria, angioedema, bronchospasm, anaphylaxis), particularly in individuals with repeated occupational exposure to Fibogel powder/dust (e.g. healthcare workers); oesophageal or intestinal obstruction if taken with insufficient fluid or in patients with strictures.

Patients should seek prompt medical attention for chest pain, difficulty swallowing, or signs of an allergic reaction after taking Fibogel.

Pregnancy: Fibogel is not systemically absorbed and is generally regarded as one of the preferred options for managing constipation during pregnancy; however, it should be used only if clearly needed, and a physician should be consulted before use, particularly for prolonged use.

Lactation: Because Fibogel acts locally in the gut and is not absorbed into the bloodstream, it is not expected to pass into breast milk in clinically relevant amounts; nonetheless, breastfeeding mothers should consult a physician before use.

Fibogel must always be taken with an adequate amount of fluid (at least one full glass of water per dose, plus an additional glass afterward) to reduce the risk of oesophageal or intestinal obstruction/choking - see Contraindications for patients in whom this risk is greatest (swallowing difficulty, strictures, bowel obstruction).

• Do not take Fibogel if experiencing a sudden change in bowel habit persisting more than 2 weeks, unexplained rectal bleeding, or failure to pass stool after use, without consulting a physician, as these may indicate an underlying condition requiring evaluation.
• Diabetic patients using sugar-containing formulations of Fibogel should choose a sugar-free preparation where available.
• Healthcare personnel who regularly handle Fibogel powder should minimise inhalation of dust, as repeated exposure has been linked to occupational sensitisation and asthma (see Side Effects).
• Onset of laxative effect is gradual (12-72 hours); it is not suitable when rapid bowel evacuation is required.

Overdose with Fibogel taken without adequate fluid may cause abdominal distension, severe bloating, or intestinal/oesophageal obstruction. If a large amount of Fibogel has been ingested, especially without sufficient water, or if severe abdominal pain, vomiting, or inability to pass stool or gas develops, seek immediate medical attention or contact a poison control centre/emergency services. Do not attempt to self-treat a suspected obstruction at home.

Store Fibogel at room temperature (below 30°C), in a tightly closed container, away from light and moisture. Keep out of reach of children.

Children

Use of Fibogel in children under 6 years is not recommended without medical supervision. In children aged 6-12 years, use only under a physician's guidance at an appropriately reduced dose (see dosing table). Safety and efficacy of Fibogel in children under 6 years have not been established.

Elderly

No dose adjustment of Fibogel is generally required in elderly patients; however, adequate fluid intake is especially important, as this population may have reduced thirst sensation and higher baseline risk of swallowing difficulty or bowel motility problems.

Renal/hepatic impairment

No specific dose adjustment of Fibogel is established for renal or hepatic impairment, as it is not systemically absorbed; however, caution and physician guidance are advised, especially in patients on fluid restriction.

Fibogel may be used for short-term relief of occasional constipation or, under medical guidance, for longer-term maintenance therapy in chronic constipation or IBS. If symptoms do not improve within 5-7 days of regular use, or if rectal bleeding occurs, a physician should be consulted rather than continuing self-treatment indefinitely.

Ispaghula Husk is classified under bulk-forming laxatives / dietary fibre supplements (hydrophilic mucilloids).

Ispaghula Husk works by absorbing water in the intestinal lumen and swelling to form a soft, bulky gel. This increases stool volume, softens its consistency, and mechanically stimulates peristalsis, promoting easier, more regular bowel movements without stimulant laxative action.

Use of Fibogel in children should occur only under medical or parental supervision, with adequate fluid intake. It is generally used for constipation in children aged 6 years and above at a reduced dose (see dosing table in Dosage and Administration). Safety and efficacy of Fibogel in children under 6 years have not been established, and it should not be used in this age group without physician advice.